ATE293700T1 - Adenovirus mit glutathion peroxydate gene - Google Patents

Adenovirus mit glutathion peroxydate gene

Info

Publication number
ATE293700T1
ATE293700T1 AT95926429T AT95926429T ATE293700T1 AT E293700 T1 ATE293700 T1 AT E293700T1 AT 95926429 T AT95926429 T AT 95926429T AT 95926429 T AT95926429 T AT 95926429T AT E293700 T1 ATE293700 T1 AT E293700T1
Authority
AT
Austria
Prior art keywords
adenovirus
glutathione
peroxydate
genes
relates
Prior art date
Application number
AT95926429T
Other languages
English (en)
Inventor
Martine Barkats
Jacques Mallet
Frederic Revah
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of ATE293700T1 publication Critical patent/ATE293700T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0065—Oxidoreductases (1.) acting on hydrogen peroxide as acceptor (1.11)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y111/00—Oxidoreductases acting on a peroxide as acceptor (1.11)
    • C12Y111/01—Peroxidases (1.11.1)
    • C12Y111/01009—Glutathione peroxidase (1.11.1.9)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
AT95926429T 1994-08-12 1995-07-26 Adenovirus mit glutathion peroxydate gene ATE293700T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9409982A FR2723588B1 (fr) 1994-08-12 1994-08-12 Adenovirus comprenant un gene codant pour la glutathion peroxydase
PCT/FR1995/001002 WO1996005320A1 (fr) 1994-08-12 1995-07-26 Adenovirus comprenant un gene codant pour la glutathion peroxydase

Publications (1)

Publication Number Publication Date
ATE293700T1 true ATE293700T1 (de) 2005-05-15

Family

ID=9466290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95926429T ATE293700T1 (de) 1994-08-12 1995-07-26 Adenovirus mit glutathion peroxydate gene

Country Status (14)

Country Link
US (2) US20010029249A1 (de)
EP (1) EP0775213B1 (de)
JP (1) JPH10504193A (de)
AT (1) ATE293700T1 (de)
AU (1) AU710727B2 (de)
CA (1) CA2197235C (de)
DE (1) DE69534165T2 (de)
FI (1) FI970579A0 (de)
FR (1) FR2723588B1 (de)
IL (1) IL114904A0 (de)
MX (1) MX9700851A (de)
NO (1) NO970282D0 (de)
WO (1) WO1996005320A1 (de)
ZA (1) ZA956678B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6814962B1 (en) * 1994-06-02 2004-11-09 Aventis Pharma S.A. Recombinant viruses and their use for treatment of atherosclerosis and other forms of coronary artery disease and method, reagent, and kit for evaluating susceptibility to same
US6544523B1 (en) 1996-11-13 2003-04-08 Chiron Corporation Mutant forms of Fas ligand and uses thereof
US6200799B1 (en) * 1997-06-03 2001-03-13 University Of Lausanne Somatic gene therapy to suppress secondary cataract formation following eye surgery
CA2671261A1 (en) 1997-11-06 1999-05-20 Novartis Vaccines And Diagnostics S.R.L. Neisserial antigens
EP1047784B2 (de) 1998-01-14 2015-03-18 Novartis Vaccines and Diagnostics S.r.l. Antigene aus neisseria meningitidis
EP2261338A3 (de) 1998-05-01 2012-01-04 Novartis Vaccines and Diagnostics, Inc. Antigene und Zusammensetzungen gegen Neisseria meningitidis
WO2000066741A2 (en) 1999-04-30 2000-11-09 Chiron S.P.A. Conserved neisserial antigens
GB9911683D0 (en) 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9916529D0 (en) 1999-07-14 1999-09-15 Chiron Spa Antigenic peptides
JP2004508801A (ja) 1999-10-29 2004-03-25 カイロン　ソチエタ　ア　レスポンサビリタ　リミタータ ナイセリア抗原性ペプチド
PT2289545T (pt) 2000-01-17 2016-09-06 Glaxosmithkline Biologicals Sa Vacina de omv suplementada contra meningococos
CA2881568C (en) 2000-10-27 2019-09-24 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from streptococcus groups a & b
GB0107658D0 (en) 2001-03-27 2001-05-16 Chiron Spa Streptococcus pneumoniae
GB0107661D0 (en) 2001-03-27 2001-05-16 Chiron Spa Staphylococcus aureus
RU2331435C2 (ru) 2001-12-12 2008-08-20 Чирон Срл. Иммунизация против chlamydia trachomatis
WO2003051313A2 (en) * 2001-12-18 2003-06-26 Brassica Foundation For Chemoprotection Research, Inc. Prevention and treatment of oxidative stress disorders by glutathione and phase ii detoxification enzymes
GB0308198D0 (en) 2003-04-09 2003-05-14 Chiron Srl ADP-ribosylating bacterial toxin
JP4792390B2 (ja) 2004-03-29 2011-10-12 株式会社ガルファーマ 新規ガレクチン９改変体タンパク質及びその用途
PT2054431E (pt) 2006-06-09 2011-11-03 Novartis Ag Confórmeros de adesinas bacterianas
EP3584312A1 (de) * 2014-06-27 2019-12-25 Angiocrine Bioscience, Inc. Nervenzellen zur expression des adenovirus e4orf1 und verfahren zur herstellung und verwendung davon
CN110108883A (zh) * 2018-10-27 2019-08-09 广州呼吸健康研究院 用于筛选与靶治疗ards患者的msc精准医学的标志物组合
JP2024017195A (ja) * 2022-07-27 2024-02-08 前澤工業株式会社 イオン交換樹脂の再生装置及び再生方法
WO2025101837A1 (en) * 2023-11-10 2025-05-15 Eccletech Llc Biological devices and methods of using the same for detection of different types of cancer

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007541A1 (en) * 1987-04-01 1988-10-06 Chiron Corporation Polynucleotide construct encoding a polypeptide substantially similar to human glutathione peroxidase
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
JPH0327289A (ja) 1989-06-22 1991-02-05 Toyo Jozo Co Ltd 新規な血漿型グルタチオン・パーオキシダーゼ遺伝子およびその用途
WO1993020195A1 (en) * 1992-04-01 1993-10-14 Fox Chase Cancer Center Method and recombinant cells for providing increased resistance of hematopoietic progenitor cells to toxicity of chemotherapeutic agents
WO1994027612A1 (en) 1993-05-20 1994-12-08 Baylor College Of Medicine Genetic therapy for cardiovascular disease
US5543328A (en) * 1993-08-13 1996-08-06 Genetic Therapy, Inc. Adenoviruses having modified fiber proteins
US7252989B1 (en) * 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system

Also Published As

Publication number Publication date
IL114904A0 (en) 1995-12-08
NO970282L (no) 1997-01-22
AU710727B2 (en) 1999-09-30
US7241591B2 (en) 2007-07-10
US20010029249A1 (en) 2001-10-11
MX9700851A (es) 1997-04-30
DE69534165D1 (de) 2005-05-25
ZA956678B (en) 1996-03-20
AU3082695A (en) 1996-03-07
NO970282D0 (no) 1997-01-22
FI970579L (fi) 1997-02-11
EP0775213B1 (de) 2005-04-20
WO1996005320A1 (fr) 1996-02-22
FR2723588B1 (fr) 1996-09-20
FI970579A7 (fi) 1997-02-11
CA2197235A1 (fr) 1996-02-22
US20040175363A1 (en) 2004-09-09
CA2197235C (fr) 2010-07-20
FR2723588A1 (fr) 1996-02-16
FI970579A0 (fi) 1997-02-11
JPH10504193A (ja) 1998-04-28
DE69534165T2 (de) 2006-03-09
EP0775213A1 (de) 1997-05-28

Similar Documents

Publication Publication Date Title
ATE293700T1 (de) Adenovirus mit glutathion peroxydate gene
UA66417C2 (en) Recombinant adenovirus affecting canines, pharmaceutical composition
RU95108217A (ru) Дефектный рекомбинантный аденовирус, линия клеток, фармацевтическая композиция
NO962791D0 (no) Preparater inneholdende nukleinsyrer, deres fremstilling og anvendelse
FI971613A7 (fi) Defektiivisiä adenoviruksia, jotka käsittävät terapeuttisen geenin ja immunoprotektiivisen geenin
TR200200938T2 (tr) CCR5 modülatörleri olarak piperidinler
MX9800719A (es) Proteinas de transporte y sus usos.
CY1109367T1 (el) Συνθεσεις και μεθοδοι για ενισχυση της παροχης θεραπευτικων παραγοντων σε κυτταρα
IL138665A0 (en) Peptide factor
IL181695A0 (en) Methods for cultivating cells and propagating viruses
ES2168457T3 (es) Composiciones farmaceuticas que comprenden una superoxido dismutasa.
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
BG103968A (en) Pharmaceutical antiviral composition containing glycirricinic acid and at least one protein with antiviral activity
ATE273031T1 (de) Aminobiguanide und ihre verwendung zur desinfektion von kontaktlinsen und konservierung von pharmazeutischen zubereitungen
TR199802648A2 (xx) Gen tedavisi i�in n�klein asit yap�lar�.
IT1270618B (it) Proteine ad attivita' antitumorale
BR9713981A (pt) Vetor recombinante para a expressão induzìvel e hepatoespecìfica de uma molécula, adenovìrus recombinante, vetor adenoviral, variante do promotor do gene da apolipoproteìna aii humana, célula, composição farmacêutica, processo para produção de uma proteìna recombinante, e, utilização de um adenovìrus
NO20000990L (no) Fremgangsmõter og sammensetninger for behandlinger som anvender gener som koder for utskilte proteiner sõ som interferon <beta>
DE69737992D1 (de) Genetische abschaffung und austausch
DE69718047D1 (de) Therapeutische verwendung von bpi proteineprodukten bei patienten mit zystischer fibrose
IT1294967B1 (it) Composizione immunogenica da tlp
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
BR9407357A (pt) Novos tripeptideos utilizáveis em terapia cns e imune
TR199700842T1 (xx) �nsan DNase I Varyantlar�.
EP0806477A4 (de) Rekombinante dna, hergestellt durch einbau von dna, die für ein isoform der schwerenkette von myoglobin sm1 kodiert in vektor-dna, sowie ein mikroorganismus und ein mittel gegen arteriosklerose, welche die rekombinante dna enthalten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties